10 employees
Ducentis is a pre-clinical stage company that aims to develop novel therapies for inflammation and autoimmune disease.
2015
$1.1M
from 3 investors over 3 rounds
Ducentisbio raised $1.1M on August 1, 2017
Investors: Capital Cell and Oxford Technology Management
Ducentisbio raised $121K on December 14, 2015
Investors: Oxford Technology Management